SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,626,988 | -15.7% | 59,013 | -8.1% | 0.00% | 0.0% |
Q2 2023 | $1,929,822 | -19.2% | 64,199 | -2.6% | 0.00% | -25.0% |
Q1 2023 | $2,389,187 | +0.9% | 65,945 | -0.6% | 0.00% | 0.0% |
Q4 2022 | $2,366,812 | +7.0% | 66,353 | +1.6% | 0.00% | 0.0% |
Q3 2022 | $2,211,000 | +14.8% | 65,313 | -1.9% | 0.00% | +33.3% |
Q2 2022 | $1,926,000 | -10.3% | 66,590 | +0.2% | 0.00% | 0.0% |
Q1 2022 | $2,147,000 | +2.4% | 66,433 | -7.6% | 0.00% | +50.0% |
Q4 2021 | $2,096,000 | +12.5% | 71,871 | +2.9% | 0.00% | 0.0% |
Q3 2021 | $1,863,000 | -10.8% | 69,837 | +3.0% | 0.00% | -33.3% |
Q2 2021 | $2,088,000 | +8.4% | 67,799 | -7.8% | 0.00% | 0.0% |
Q1 2021 | $1,926,000 | +3.5% | 73,562 | -0.5% | 0.00% | 0.0% |
Q4 2020 | $1,860,000 | +21.3% | 73,940 | +0.5% | 0.00% | +50.0% |
Q3 2020 | $1,533,000 | -12.2% | 73,553 | 0.0% | 0.00% | -33.3% |
Q2 2020 | $1,747,000 | +30.4% | 73,553 | -1.2% | 0.00% | 0.0% |
Q1 2020 | $1,340,000 | -25.0% | 74,479 | -1.1% | 0.00% | 0.0% |
Q4 2019 | $1,787,000 | -15.4% | 75,320 | -2.0% | 0.00% | -25.0% |
Q3 2019 | $2,112,000 | -15.9% | 76,841 | +1.2% | 0.00% | -20.0% |
Q2 2019 | $2,512,000 | -4.4% | 75,924 | +1.3% | 0.01% | 0.0% |
Q1 2019 | $2,627,000 | +3.2% | 74,977 | -2.2% | 0.01% | -16.7% |
Q4 2018 | $2,546,000 | -32.5% | 76,644 | +2.3% | 0.01% | -14.3% |
Q3 2018 | $3,772,000 | -15.9% | 74,915 | -0.0% | 0.01% | -22.2% |
Q2 2018 | $4,485,000 | +33.1% | 74,942 | +1.9% | 0.01% | +28.6% |
Q1 2018 | $3,369,000 | +11.0% | 73,563 | -3.4% | 0.01% | +16.7% |
Q4 2017 | $3,034,000 | -0.0% | 76,142 | +0.3% | 0.01% | -14.3% |
Q3 2017 | $3,035,000 | -16.1% | 75,880 | -9.6% | 0.01% | -12.5% |
Q2 2017 | $3,619,000 | +25.2% | 83,974 | -9.1% | 0.01% | +33.3% |
Q1 2017 | $2,891,000 | +18.3% | 92,380 | -4.5% | 0.01% | +20.0% |
Q4 2016 | $2,444,000 | -0.4% | 96,780 | -2.5% | 0.01% | 0.0% |
Q3 2016 | $2,455,000 | +22.5% | 99,280 | +0.9% | 0.01% | +25.0% |
Q2 2016 | $2,004,000 | +80.5% | 98,380 | +35.2% | 0.00% | +100.0% |
Q1 2016 | $1,110,000 | -80.6% | 72,783 | -82.9% | 0.00% | -85.7% |
Q4 2015 | $5,708,000 | +550.9% | 424,712 | +579.2% | 0.01% | +600.0% |
Q3 2015 | $877,000 | -74.7% | 62,534 | -69.4% | 0.00% | -75.0% |
Q2 2015 | $3,472,000 | +436.6% | 204,483 | +282.3% | 0.01% | +300.0% |
Q1 2015 | $647,000 | +43.5% | 53,483 | -1.5% | 0.00% | +100.0% |
Q4 2014 | $451,000 | -4.0% | 54,283 | +0.4% | 0.00% | 0.0% |
Q3 2014 | $470,000 | -19.7% | 54,052 | +1.1% | 0.00% | 0.0% |
Q2 2014 | $585,000 | +77.8% | 53,445 | +45.4% | 0.00% | 0.0% |
Q1 2014 | $329,000 | +48.2% | 36,745 | +24.8% | 0.00% | 0.0% |
Q4 2013 | $222,000 | +13.8% | 29,445 | +10.5% | 0.00% | 0.0% |
Q3 2013 | $195,000 | +16.8% | 26,645 | +2.7% | 0.00% | 0.0% |
Q2 2013 | $167,000 | +297.6% | 25,945 | +246.8% | 0.00% | – |
Q1 2013 | $42,000 | – | 7,482 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |